AIDS-associated Kaposi's sarcoma: Is there still a role for interferon alfa?

Cytokine and Growth Factor Reviews

Volumn 18, Issue 5-6, 2007, Pages 395-402

  Krown, Susan E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Interferon; Kaposi's sarcoma

Indexed keywords

ALPHA INTERFERON; DIDANOSINE; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2A INTERFERON; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOGENESIS; ANOREXIA; ARTICLE; CELL CYCLE REGULATION; CLINICAL TRIAL; CYTOPENIA; DRUG ACTIVITY; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; LIVER FUNCTION TEST; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIDE EFFECT; TUMOR REGRESSION; VIRUS REPLICATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIVIRAL AGENTS; HUMANS; INTERFERON-ALPHA; SARCOMA, KAPOSI;

HUMAN HERPESVIRUS 8;

EID: 34548132435     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2007.06.005     Document Type: Article

References (74)

1. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220 (1983) 868-871
2. Chang Y., Cesarman E., Pessin M.S., Lee F., Culpepper J., Knowles D.M., et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266 (1994) 1865-1869
3. Centers for Disease Control. Kaposi's sarcoma and pneumocystis pneumonia among homosexual men: New York City and California. MMWR 30 (1981) 305-308
4. Gottlieb M.S., Schroff R., Schanker H.M., Weisman J.D., Fan P.T., Wolf R.A., et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 305 (1981) 1425-1431
5. Siegal F.P., Lopez C., Hammer G.S., Brown A.E., Kornfeld S.J., Gold J., et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 305 (1981) 1439-1444
6. Masur H., Michelis M.A., Greene J.B., Onorato I., Stouwe R.A., Holzman R.S., et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 305 (1981) 1431-1438
7. Krown S.E., Real F.X., Cunningham-Rundles S., Myskowski P.L., Koziner B., Fein S., et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 308 (1983) 1071-1076
8. Giraldo G., Beth E., Kourilsky F.M., Henle W., Henle G., Mike V., et al. Antibody patterns to herpesviruses in Kaposi's sarcoma: serological association of European Kaposi's sarcoma with cytomegalovirus. Int J Cancer 15 (1975) 839-848
9. Giraldo G., Beth E., Henle W., Henle G., Mike V., Safai B., et al. Antibody patterns to herpesviruses in Kaposi's sarcoma. II. Serological association of American Kaposi's sarcoma with cytomegalovirus. Int J Cancer 22 (1978) 126-131
10. Real F.X., Oettgen H.F., and Krown S.E. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 4 (1986) 544-551
11. Vadhan-Raj S., Wong G., Gnecco C., Cunningham-Rundles S., Krim M., Real F.X., et al. Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome. Cancer Res 46 (1986) 417-425
12. Hartshorn K.L., Vogt M.W., Chou T.C., Blumberg R.S., Byington R., Schooley R.T., et al. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother 31 (1987) 168-172
13. Krown S.E., Gold J.W., Niedzwiecki D., Bundow D., Flomenberg N., Gansbacher B., et al. Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 112 (1990) 812-821 [Erratum in: Ann Intern Med 1990;113:334]
14. Berman E., Duigou-Osterndorf R., Krown S.E., Fanucchi M.P., Chou J., Hirsch M.S., et al. Synergistic cytotoxic effect of azidothymidine and recombinant interferon alpha on normal human bone marrow progenitor cells. Blood 74 (1989) 1281-1286
15. Krown S.E., Paredes J., Bundow D., Polsky B., Gold J.W., and Flomenberg N. Interferon-alpha, zidovudine, and granulocyte-macrophage colony-stimulating factor: a phase I AIDS Clinical Trials Group study in patients with Kaposi's sarcoma associated with AIDS. J Clin Oncol 10 (1992) 1344-1351
16. Mildvan D., Bassiakos Y., Zucker M.L., Hyslop Jr. N., Krown S.E., Sacks H.S., et al. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068. Antivir Ther 1 (1996) 77-88
17. Krown S.E., Aeppli D., and Balfour Jr. H.H. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team. J Acquir Immune Defic Syndr Hum Retrovirol 20 (1999) 245-254
18. Krown S.E., Li P., Von Roenn J.H., Paredes J., Huang J., and Testa M.A. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res 22 (2002) 295-303
19. Wang H.-W., Trotter M.W.B., Lagos D., Bourboulia D., Makinen T., Elliman S., et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 36 (2004) 687-693
20. Ensoli B., Nakamura S., Salahuddin S.Z., Biberfeld P., Larsson L., Beaver B., et al. AIDS Kaposi's sarcoma derived cells express cytokines with autocrine and paracrine growth effects. Science 243 (1989) 223-226
21. Miles S.A., Rezai A.R., Salazar-Gonzales J.F., Vander-Meyden M., Stevens R.H., Logan D.M., et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 87 (1990) 4068-4072
22. Samaniego F., Markham P.D., Gendleman R., Watanabe Y., Kao V., Kowalski K., et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 152 (1998) 1433-1443
23. Koon H.B., Bubley G.J., Pantanowitz L., Masiello D., Smith B., Crosby K., et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 23 (2005) 982-989
24. Stallone G., Schena A., Infante B., Di Paolo S., Loverre A., Maggio G., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317-1323
25. Meade-Tollin L.C., Way D., and Witte M.H. Expression of multiple matrix metalloproteinases and urokinase type plasminogen activator in cultured Kaposi sarcoma cells. Acta Histochem 101 (1999) 305-316
26. Barillari G., Sgadari C., Palladino C., Gendelman R., Caputo A., Morris C.B., et al. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol 163 (1999) 1929-1935
27. Friborg Jr. J., Kong W., and Hottiger M.O. Nabel GA. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402 (1999) 889-894
28. Swanton C., Mann D.J., Fleckenstein B., Neipel F., Peters G., and Jones N. Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390 (1997) 184-187
29. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
30. Samaniego F., Pati S., Karp J.E., Prakash O., and Bose D. Human herpesvirus 8 K1-associated nuclear factor-kappa B-dependent promoter activity: role in Kaposi's sarcoma inflammation?. J Natl Cancer Inst Monogr 28 (2001) 15-23
31. Sarid R., Sato T., Bohenzky R.A., Russo J.J., and Chang Y. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nat Med 3 (1997) 293-298
32. Dourmishev L.A., Dourmishev A.L., Palmeri D., Schwartz R.A., and Lukac D.M. Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis. Microbiol Mol Biol Rev 67 (2003) 175-212
33. Jenner R.G., and Boshoff C. The molecular pathology of Kaposi's sarcoma-associated herpesvirus. Biochim Biophys Acta 1602 (2002) 1-22
34. Bais C., Santomasso B., Coso O., Arvanitakis L., Raaka E.G., Gutkind J.S., et al. G-protein coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391 (1998) 86-89
35. Yang T.Y., Chen S.C., Leach M.W., Manfra D., Homey B., Wiekowski M., et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 191 (2000) 445-454
36. Weindel K., Marme D., and Weich H.A. AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor. Biochem Biophys Res Commun 183 (1992) 1167-1174
37. Bais C., Van Geelen A., Eroles P., Mutlu A., Chiozzini C., Dias S., et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell 3 (2003) 131-143
38. Wang L., Wakisaka N., Tomlinson C.C., DeWire S.M., Krall S., Pagano J.S., et al. The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res 64 (2004) 2774-2781
39. Rivas C., Thlick A.E., Parravicini C., Moore P.S., and Chang Y. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol 75 (2001) 429-438
40. Burysek L., Yeow W.S., Lubyova B., Kellum M., Schafer S.L., Huang Y.Q., et al. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J Virol 73 (1999) 7334-7342
41. Li M., Lee H., Guo J., Neipel F., Fleckenstein B., Ozato K., et al. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor. J Virol 72 (1998) 5433-5440
42. Dittmer D.P. Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays. Cancer Res 63 (2003) 2010-2015
43. Djerbi M., Screpanti V., Catrina A.I., Bogen B., Biberfeld P., and Grandien A. The inhibitor of death-receptor signalling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 190 (1999) 1025-1032
44. Weber K.S., Grone H.J., Rocken M., Klier C., Gu S., Wank R., et al. Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-II. Eur J Immunol 31 (2001) 2458-2466
45. Lee B.S., Alvarez X., Ishido S., Lackner A.A., and Jung J.U. Inhibition of intracellular transport of B cell antigen receptor complexes by Kaposi's sarcoma-associated herpesvirus K1. J Exp Med 192 (2000) 11-21
46. Coscoy L., and Ganem D. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc Natl Acad Sci USA 97 (2000) 8051-8056
47. Staskus K.A., Zhong W., Gebhard K., Herndier B., Wang H., Renne R., et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 71 (1997) 715-719
48. Orenstein J.M., Alkan S., Blauvelt A., Jeanq K.T., Weinstein M.D., Ganem D., et al. Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy. AIDS 11 (1997) F35-F45
49. Toschi E., Bacigalupo I., Strippoli R., Chiozzini C., Cereseto A., Falchi M., et al. HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway. Mol Biol Cell 17 (2006) 1985-1994
50. Ho D.D., Hartshorn K.L., Rota T.R., Andrews C.A., Kaplan J.C., Schooley R.T., et al. Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet 16 (1985) 602-604
51. Johnson V.A., Merrill D.P., Videler J.A., Chou T.C., Byington R.E., Eron J.J., et al. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis 164 (1991) 646-655
52. Vogt M.W., Durno A.G., Chou T.C., Coleman L.A., Paradis T.J., Schooley R.T., et al. Synergistic interaction of 2′,3′-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1. J Infect Dis 158 (1988) 378-385
53. Monini P., Carlini F., Sturzl M., Rimessi P., Superti F., Franco M., et al. Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells. J Virol 73 (1999) 4029-4041
54. D'Agostino G., Arico E., Santodonato L., Venditti M., Sestili P., Masuelli L., et al. Type I consensus IFN (IFN-con1) gene transfer into KSHV/HHV-8-infected BCBL-1 cells causes inhibition of viral lytic cycle activation via induction of apoptosis and abrogates tumorigenicity in sCID mice. J Interferon Cytokine Res 19 (1999) 1305-1316
55. Wu W., Rochford R., Toomey L., Harrington Jr. W., and Feuer G. Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha. Leukemia Res 29 (2005) 545-555
56. Chang J., Renne R., Dittmer D., and Ganem D. Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. Virology 266 (2000) 17-25
57. Krown S.E., Lee J.Y., Lin L., Fischl M.A., Ambinder R., and Von Roenn J.H. Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial. J Acquir Immune Defic Syndr 41 (2006) 149-153
58. Brouty-Boye D., and Zetter B.R. Inhibition of cell motility by interferon. Science 208 (2000) 516-518
59. Sidky Y.A., and Borden E.C. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 47 (1987) 5155-5161
60. Dvorak H.F., and Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 81 (1989) 497-502
61. Oliveira I.C., Sciavolino P.J., Lee T.H., and Vilcek J. Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc Natl Acad Sci USA 89 (1992) 9049-9053
62. Singh R.K., Gutman M., Bucana C.D., Sanchez R., Llansa N., and Fidler I.J. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 92 (1995) 4562-4566
63. Dinney C.P., Bielenberg D.R., Perrotte P., Reich R., Eve B.Y., Bucana C.D., et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 58 (1998) 808-814
64. Slaton J.W., Perrotte P., Inoue K., Dinney C.P., and Fidler I.J. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5 (1999) 2726-2734
65. Ozawa S., Shinohara H., Kanayama H.O., Bruns C.J., Bucana C.D., Ellis L.M., et al. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia 3 (2001) 154-164
66. Ezekowitz R.A., Mulliken J.B., and Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326 (1992) 1456-1463 [Erratum in: N Engl J Med 1994;330:300. N Engl J Med 1995;333:595-6]
67. von Marschall Z., Scholz A., Cramer T., Schafer G., Schirner M., Oberg K., et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 95 (2003) 437-448
68. Tosato G. Interferon-alpha is implicated in the transcriptional regulation of vascular endothelial growth factor. J Natl Cancer Inst 95 (2003) 420-421
69. Engels E.A., Pfeiffer R.M., Goedert J.J., Virgo P., McNeel T.S., Scoppa S.M., et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 20 (2006) 1645-1654
70. Sitas F., and Newton R. Kaposi's sarcoma in South Africa. J Natl Cancer Inst Monogr 28 (2001) 1-4
71. Chokunonga E., Levy L.M., Bassett M.T., Borok M.Z., Mauchaza B.G., Chirenje M.Z., et al. AIDS and cancer in Africa: the evolving epidemic in Zimbabwe. AIDS 13 (1999) 2583-2588
72. Parkin D.M., Wabinga H., Nambooze S., and Wabwire-Mangen F. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS 13 (1999) 2563-2570
73. Dezube B.J., Krown S.E., Lee J.Y., Bauer K.S., and Aboulafia D.M. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 24 (2006) 1389-1394
74. Parmar S., Smith J., Sassano A., Uddin S., Katsoulidis E., Majchrzak B., et al. Differential regulation of the p70 S6 kinase pathway by interferon α (IFNα) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 106 (2006) 2436-2443